NasdaqCM - Delayed Quote • USD
Senti Biosciences, Inc. (SNTI)
At close: April 25 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,978.0000
1,978.0000
3,286.0000
2,291.0000
394.0000
Operating Expense
68,743.0000
68,743.0000
65,370.0000
42,737.0000
25,088.0000
Operating Income
-66,765.0000
-66,765.0000
-62,084.0000
-40,446.0000
-24,694.0000
Net Non Operating Interest Income Expense
2,864.0000
2,864.0000
1,701.0000
11.0000
88.0000
Other Income Expense
-19,505.0000
-19,505.0000
10,718.0000
-14,884.0000
4,744.0000
Pretax Income
-83,406.0000
-83,406.0000
-49,665.0000
-55,319.0000
-19,862.0000
Net Income Common Stockholders
-71,058.0000
-71,058.0000
-58,210.0000
-55,319.0000
-19,862.0000
Diluted NI Available to Com Stockholders
-71,058.0000
-71,058.0000
-58,210.0000
-55,319.0000
-19,862.0000
Basic EPS
-1.60
--
-2.23
-1.27
-0.45
Diluted EPS
-1.60
--
-2.23
-1.27
-0.45
Basic Average Shares
44,372.2230
--
26,110.7850
43,657.0770
43,657.0770
Diluted Average Shares
44,372.2230
--
26,110.7850
43,657.0770
43,657.0770
Total Operating Income as Reported
-92,727.0000
-92,727.0000
-62,084.0000
-40,446.0000
-24,694.0000
Total Expenses
68,743.0000
68,743.0000
65,370.0000
42,737.0000
25,088.0000
Net Income from Continuing & Discontinued Operation
-71,058.0000
-71,058.0000
-58,210.0000
-55,319.0000
-19,862.0000
Normalized Income
-61,611.0000
-61,611.0000
-60,415.0000
-55,297.0000
-19,624.0000
Interest Income
2,864.0000
2,864.0000
1,701.0000
11.0000
88.0000
Net Interest Income
2,864.0000
2,864.0000
1,701.0000
11.0000
88.0000
EBIT
-66,765.0000
-66,765.0000
-62,084.0000
-40,446.0000
-24,694.0000
EBITDA
-61,336.0000
-61,336.0000
-58,164.0000
-37,436.0000
-22,709.0000
Reconciled Depreciation
5,429.0000
5,429.0000
3,920.0000
3,010.0000
1,985.0000
Net Income from Continuing Operation Net Minority Interest
-83,406.0000
-83,406.0000
-49,665.0000
-55,319.0000
-19,862.0000
Total Unusual Items Excluding Goodwill
-21,795.0000
-21,795.0000
10,750.0000
-22.0000
-238.0000
Total Unusual Items
-21,795.0000
-21,795.0000
10,750.0000
-22.0000
-238.0000
Normalized EBITDA
-39,541.0000
-39,541.0000
-68,914.0000
-37,414.0000
-22,471.0000
12/31/2020 - 5/26/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VRAX Virax Biolabs Group Limited
0.7000
+7.53%
XCUR Exicure, Inc.
0.5090
-1.17%
QNRX Quoin Pharmaceuticals, Ltd.
0.6300
-1.95%
SXTP 60 Degrees Pharmaceuticals, Inc.
0.2336
-3.59%
SPRC SciSparc Ltd.
1.2600
+4.13%
RNAZ TransCode Therapeutics, Inc.
0.5250
+19.35%
ONCO Onconetix, Inc.
0.1204
-1.39%
TCBP TC Biopharm (Holdings) Plc
1.5700
+6.80%
QUIA.ST QuiaPEG Pharmaceuticals Holding AB (publ)
0.0712
-3.52%
KPRX Kiora Pharmaceuticals, Inc.
0.4800
-5.10%